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Atomoxetine in Autism Spectrum Disorder:
No Effects on Social Functioning; Some Beneficial
Effects on Stereotyped Behaviors, Inappropriate
Speech, and Fear of Change
Myriam Harfterkamp, MD,1 Jan K. Buitelaar, MD, PhD,2,3 Ruud B. Minderaa, MD, PhD,1
Gigi van de Loo-Neus, MD,2 Rutger-Jan van der Gaag, MD,2 and Pieter J. Hoekstra, MD, PhD1
Abstract
Objective: The objective of this study was to investigate the short-term treatment effects of atomoxetine on autism spectrum
disorder (ASD) symptoms in children and adolescents with both ASD and attention-deficit/hyperactivity disorder (ADHD).
Methods: A total of 97 patients 6–17 years of age, with ASD and ADHD, were treated with 1.2mg/kg/day of atomoxetine
during an 8 week double-blind placebo-controlled period. Here, we investigated effects on two parent-based secondary
outcome measures, the Aberrant Behavior Checklist (ABC) and the Children’s Social Behavior Questionnaire (CSBQ).
Results: After 8 weeks of double-blind treatment, atomoxetine administration was associated with significant treatment
effects on theABC subscales Hyperactivity, Inappropriate Speech, and Stereotypic Behavior, and on theCSBQ subscale Fear
for Changes.
Conclusions: Our study results indicate no beneficial effects of atomoxetine on social functioning. However, atomoxetine
may ameliorate restricted and stereotyped behaviors and communication.
This study has been registered in ClinicalTrials.gov (www.clinicaltrials.gov) under registration number NCT00380692.
Introduction
Autism spectrum disorders (ASD) are a continuum ofdevelopmental disorders characterized by impairments in
social interaction and verbal and nonverbal communication skills,
and stereotyped behaviors, often with various comorbid features
such as attention-deficit/hyperactivity disorder (ADHD) symp-
toms, self-injurious behavior, aggression, mood problems, sensory
differences, sleep dysfunction, and intolerance of change (Leyfer
et al. 2006).
There is currently no curative treatment for ASD. The overall
treatment goal is to improve the child’s functioning, ideally by
reducing impairments in social interaction and communication, and
repetitive behaviors. Behavioral interventions can improve chil-
dren’s language abilities, play and cognitive skills, and social
functioning, and may reduce maladaptive behavior (Dawson and
Burner 2011). Psychotropic medication may also improve chil-
dren’s functioning and allow children with ASD to benefit more
optimally from educational interventions (Anagnostou and Hansen
2011; Huffman et al. 2011).
The three classes of medication most extensively studied in ASD
clinical trials are atypical neuroleptics, psychostimulants, and se-
lective serotonin reuptake inhibitors (SSRIs). Current evidence
indicates efficacy of atypical neuroleptics for ameliorating irrita-
bility and repetitive behaviors in ASD, with the strongest level of
empirical support for risperidone and aripiprazole (McDougle et al.
2005; Marcus et al. 2009, 2011). Further, positive effects of
methylphenidate on social communication and self-regulation in
children with ASD and hyperactivity have been observed ( Jahromi
et al. 2009). Finally, a well-designed and powered study indicated
ineffectiveness of citalopram, suggesting no clear place for SSRIs
in the treatment of children with ASD (King et al. 2009).
Atomoxetine, a noradrenergic reuptake inhibitor registered for
the treatment of ADHD, may be effective in ameliorating ADHD
symptoms in children with ASD, as indicated by a number of small-
scale studies ( Jou et al. 2005; Arnold et al. 2006; Posey et al. 2006;
Troost et al. 2006) and by our placebo-controlled trial involving
almost 100 subjects (Harfterkamp et al. 2012). Some of the smaller
studies had also suggested improvements in core ASD symptoms
and social functioning (Arnold et al. 2006; Posey et al. 2006).
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Our study in children and adolescents with combined ASD and
ADHD consisted of a first 8 week double-blind period of atomox-
etine versus placebo followed by a 20 week open label continued
treatment period,and used the ADHD rating scale (ADHD-RS) as a
primary outcome measure (Faries et al. 2001). Here, we present
the possible effects of atomoxetine on ASD symptoms as inves-
tigated in the placebo-controlled part of the study, measured by
two parent-based secondary outcome measures, the Aberrant
Behavior Checklist (ABC) (Aman et al. 1985) and the Children’s
Social Behavior Questionnaire (CSBQ) (Hartman et al. 2006).
Methods
Study participants
We provided detailed inclusion criteria previously (Harfterkamp
et al. 2012). In brief, subjects had to be between 6 and 17 years of
age, have an intelligence quotient of at least 60, and have a dual
diagnosis of ASD and ADHD. ASD diagnosis was based on clinical
assessment, and had to be corroborated by at least two subscale
scores on the Autism Diagnostic Interview Revised (ADI-R) above
the cutoff (Rutter et al. 2003); ADHD diagnoses had to meet Di-
agnostic and Statistical Manual of Mental Disorders, 4th ed., Text
Revision (DSM-IV-TR) criteria A through D for ADHD any type
(American Psychiatric Association 2000). Nine Dutch child and
adolescent psychiatry centers, six university centers (Amsterdam,
Groningen, Leiden, Maastricht, Nijmegen, and Utrecht), and three
non-university centers (The Hague, Hoorn, and Oosterhout) could
recruit patients for the study. Exclusion criteria included a weight
of < 20 kg; presence of psychosis, bipolar disorder, or substance
abuse; a serious medical illness; history of seizures; ongoing use of
psychoactive medications other than the study drug; and intended
start of a structured psychotherapy or inpatient treatment.
Both parents and subjects ‡ 12 years of age had to give written
informed consent, and younger children had to assent. The study
had been approved by the national and local institutional re-
view board committees. Participants were enrolled in the placebo-
controlled study from October 2006 to March 2008.
Study interventions
Patients were randomized in a 1:1 ratio to receive either placebo
or atomoxetine capsules titrated to a fixed once-daily dose of
1.2mg/kg/day (1st week: 0.5mg/kg/day; 2nd week: 0.8mg/kg/day;
then 1.2mg/kg/day for 6 weeks).
Outcome measures
To rate changes in ASD symptoms, we used two parent-based
questionnaires, the ABC and the CSBQ, which were obtained at
baseline and at the end of the study, that is, after 8 weeks. The ABC
is a 58 item scale that consists of five subscales, labeled Irritability
(includes agitation, crying, and self-injurious behaviors, and con-
tains 15 items, e.g., screams inappropriately; is aggressive to other
children or adults; depressed mood); Lethargy/Social Withdrawal
(includes social withdrawal, has 16 items, e.g., seeks isolation from
others; does not try to communicate with words or gestures; fixed
facial expression); Stereotypic Behavior (7 items, e.g., moves or
rolls head repetitively; repetitive hand, body, or head movements);
Hyperactivity (includes noncompliance, 16 items, e.g., impulsive
[acts without thinking]; restless, unable to sit still; disobedient,
difficult to control), and Inappropriate Speech (4 items, e.g., talks
excessively; repetitive speech). The ABC was developed as a
measure of treatment effects in patients with developmental dis-
abilities. It has been used in drug research and other forms of
clinical research and has been shown to be sensitive to the effects of
psychotropic drugs (Aman et al. 1985; Troost et al. 2006; Kar-
abekiroglu and Aman 2009).
The CSBQ consists of 49 items covering a broad range of fea-
tures typical for ASD, from subtle social, communication, and re-
petitive behavioral impairments seen in children with milder forms
of ASD, to more severe autistic-like features, with an emphasis on
the former (Hartman et al. 2006). Items are rated in a three point
Likert-type fashion (i.e., 0= does not apply at all; 1 = applies
slightly or infrequently; 2= applies clearly or often). The CSBQ
consists of a total scale and six subscales: Subscale 1, Behavior/
emotions not optimally tuned to the social situation (11 items, e.g.,
does not know when to stop; goes on and on about things; makes a
fuss over little things; makes a mountain of a mole hill); Subscale 2,
Reduced contact and social interest (12 items, e.g., has little or no
need for contact with others; does not seek comfort when he/she is
hurt or upset; lives in a world of his/her own); Subscale 3, Or-
ientation problems in time, place, or activity (8 items, e.g., does
things without realizing what stage of the activity he/she is; has no
sense of time); Subscale 4, Difficulties in understanding social in-
formation (7 items, e.g., takes things literally; is exceptionally
naı¨ve); Subscale 5, Stereotyped behavior (8 items, e.g., is ex-
tremely pleased by certain movements and keeps doing them; is
fascinated by certain colors, forms, or moving objects); and Sub-
scale 6, Fear of and resistance to changes (3 items, e.g., panics in
new situations or if change occurs). Multiple estimates of reliability
and validity of the CSBQ were found to be good (Luteijn et al.
2000; Hartman et al. 2006; de Bildt et al. 2009).
Data analysis
Analyses were conducted on the full data set which, following the
intent-to-treat principle, included all randomized patients receiving
at least one dose of the study drug. Changes from baseline to 8 weeks
on the ABC subscales and the CSBQ total scale and subscales were
analyzed using analysis of covariance (ANCOVA), imputing miss-
ing values based on last observation carried forward (LOCF). AN-
COVA included fixed effects for treatment group and baseline score.
We used a p value < 0.05 to indicate statistical significance. In light
of the relatively small sample size, we did not adjust the a level for
multiple comparisons, to avoid false negative findings.
Results
Participants
Figure 1 shows the flow of the 97 participants through the study.
The baseline demographic and clinical characteristics of partici-
pants were similar between the treatment groups in the double-
blind treatment phase (Table 1). As stated in the flow diagram, 5 of
48 subjects randomized to atomoxetine and 3 of 49 subjects ran-
domized to placebo discontinued for a variety of reasons.
Outcomes
After 8 weeks of double-blind treatment, the scores on the ABC
subscales Hyperactivity, Inappropriate Speech, and Stereotypic
Behavior, and the CSBQ subscale Fear for Changes were signifi-
cantly more lowered from baseline in the atomoxetine than in the
placebo group. None of the other ABC subscales or the CSBQ total
scale or subscales showed statistically significant different change
scores from baseline to 8 weeks of treatment between the ato-
moxetine and placebo groups (Table 2).
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Discussion
The present study investigated possible effects of atomoxetine
on ASD symptoms in children with ASD and ADHD symptoms.
We used parent-based secondary outcome measures (ABC and
CSBQ) in an 8 week double-blind placebo-controlled trial. Overall,
no treatment effects were observed on the hallmark ASD symptom
domain of impairments in social interaction, as indicated by lack of
improvements on the CSBQ subscales Not Tuned, Reduced Con-
tact, and Social Information.
Still, we observed some modest improvements in other ASD
symptom domains. We found superior effects of atomoxetine on
the ABC subscales Hyperactivity, Inappropriate Speech, and Ste-
reotypic Behavior. Obviously, the effect on the ABC Hyperactivity
subscale is directly related to improvements in ADHD symptoms,
in line with our previously reported findings of superior effects of
atomoxetine compared with placebo on the clinician-based ADHD-
RS (Harfterkamp et al. 2012). The other two ABC subscales con-
tain items referring to communication and stereotyped behaviors.
These ABC findings are largely in line with two earlier, small-scale
studies with atomoxetine in children with ASD. A small-scale
double-blind placebo-controlled crossover study of clinically ti-
trated atomoxetine and placebo, 6 weeks each, separated by a 1
week washout, in 16 children and adolescents with ASD, reported
effects on the ABC subscales Hyperactivity and Lethargy/Social
Withdrawal (Arnold et al. 2006). Another 8 week open-label pro-
spective study in 16 children with ASD showed effects of
atomoxetine on the ABC subscales Hyperactivity, Stereotypic
Behavior, Lethargy/Social Withdrawal, and Inappropriate Speech
(Posey et al. 2006). It should be noted, however, that our finding of
an overall change of* 20% on the four item ABC Inappropriate
Speech subscale, although statistically significant, may not neces-
sarily point to improvement in Inappropriate Speech per se, but
could rather be related to changes in ADHD symptoms (e.g., the
ABC Inappropriate Speech item ‘‘talks excessively’’ could have
improved because of decreased ADHD symptoms rather than a
change in core features of ASD).
Fear of changes was the only CSBQ subscale on which ato-
moxetine had better effects than placebo. This is in line with pre-
vious studies that had suggested possible effects of atomoxetine on
anxiety, as found in children and adults with ADHD and an anxiety
disorder (Geller et al. 2007; Adler et al. 2009). However, better
handling of changes may also indicate an effect of atomoxetine on
ameliorating restrictive behavior, in line with the positive effects of
atomoxetine on the ABC Stereotypic Behavior subscale. It must be
noted, however, that the CSBQ Fear of Changes subscale has only
three items; with a decrease of* 20%, the improvement may not
be clinically meaningful. Also, the lack of improvement in the
Stereotypy CSBQ subscale does not substantiate the possible ef-
fects of atomoxetine on ameliorating stereotyped behaviors. Al-
though we have no direct explanation for the differing results on the
CSBQ subscale Stereotypy versus the ABC subscale Stereotypic
Behavior, the lack of consistency most likely reflects differences in
item content between these two subscales.
Limitations
A number of limitations need to be acknowledged. Perhaps the
most critical one has been the choice of rating scales to assess
improvements in ASD symptoms. For this, we relied entirely on
FIG. 1. Flow diagram of a trial of atomoxetine versus placebo in children and adolescents with autism spectrum disorder and
attention-deficit/hyperactivity disorder symptoms.
Table 1. Baseline Characteristics of Participants
in Our 8 Week Trial of Atomoxetine versus
Placebo in Children and Adolescents
with ASD and ADHD Symptoms
Characteristic Atomoxetine n = 48 Placebo n= 49
Mean age, y, (SD),
range
9.9 (2.7), 6–16 10.0 (2.9), 6–17








18 (37.5) 18 (36.7)
Autistic disorder,a n (%) 26 (54.2) 32 (65.3)
All other ASDs,b n (%) 22 (45.9) 17 (34.7)
aBased on clinical diagnosis, corroborated by ADI-R.
bBased on clinical diagnosis, corroborated by ADI-R, but two partic-
ipants (one in each treatment group) had a clinical diagnosis of ASD that
was (in deviance with the protocol) not corroborated by ADI-R scores.
ADHD, attention-deficit/hyperactivity disorder; ADI-R, Autism Diag-
nostic Interview-Revised; ASD, autism spectrum disorder; IQ, intelligence
quotient.
ATOMOXETINE’S EFFECT ON ASD SYMPTOMS 483
parent ratings, without clinical assessment, observation, or use of
teacher ratings. However, the ABC has become something of a gold
standard for trials in this area. As a second limitation, it should be
noted that the study had not been primarily powered to investigate
improvements in ASD symptoms. It cannot be excluded that a
larger sample size would still indicate effects of atomoxetine on
social behavior, even when adjusting levels of significance for
multiple comparisons.
Conclusions
In summary, our study indicates no beneficial effects of ato-
moxetine on social functioning after 8 weeks of treatment. These
results are in line with existing studies showing that social func-
tioning is not very responsive to currently available psychophar-
macological treatments that have been tested in ASD to date
(Anagnostou and Hansen 2011; Huffman et al. 2011). Still, we did
find some indication of beneficial effects of atomoxetine on ste-
reotyped behaviors, inappropriate speech, and fear of change, and
on hyperactivity. The latter finding is in line with our previously
reported improvements in ADHD symptoms (Harfterkamp et al.
2012, 2013). These benefits may help children and adolescents with
ASD to profit more from behavioral interventions, which should be
investigated in future studies.
Clinical Significance
ASD are a continuum of developmental disorders characterized
by impairments in social interaction and verbal and nonverbal
communication skills, and stereotyped behaviors, with various
frequently co-occurring problems such as symptoms of ADHD,
self-injurious behavior, aggression, mood problems, sensory dif-
ferences, sleep dysfunction, and intolerance of change. Whereas we
previously found effects of atomoxetine on ADHD symptoms in
children with ASD and co-occurring symptoms of ADHD, the
current analyses suggest no beneficial effects of atomoxetine on
social functioning. These results are in line with existing studies
showing that social functioning is not very responsive to currently
available psychopharmacological treatments that have been tested
in ASD patients to date. Still, we did find some indication of ben-
eficial effects of atomoxetine on stereotyped behaviors, inappro-
priate speech, and fear of change, and on hyperactivity.
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Table 2. Changes in ABC Subscales and CSBQ Total Scale and Subscale Scores from Baseline
to 8 Weeks of Double-Blind Treatment with Atomoxetine versus Placebo
Measure
Atomoxetine (n= 48)
Mean (SD) at baseline,
LS mean after 8 weeks
(95% CI)a
Placebo (n= 49)
Mean (SD) at baseline,




























4.7 (3.2), 3.7 (3.3–4.3) 4.6 (3.4), 4.5 (4.0–5.1) 0.4 0.9 ( - 1.7–0.0)
p= 0.045
























3.3 (1.9), 2.6 (2.3–3.0) 3.0 (1.9), 3.2 (2.8–3.5) 0.4 0.6 ( - 1.1–0.0)
p= 0.035
aBased on last observation carried forward analysis of covariance (ANCOVA)
ABC, Aberrant Behavior Checklist; CSBQ, Children’s Social Behavior Questionnaire; LS, Least Squares.
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